April 18th 2024
The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
ELVIS Results Offer Hope to Elderly Lung Cancer Patients
March 1st 1999NAPLES-Nearly one-third of the estimated 144,000 new non-small-cell lung cancer (NSCLC) patients diagnosed in the United States each year are over the age of 65, and these patients often do not have access to the range of treatment options available to younger patients. Platinum-based therapy is often avoided due to concerns about tolerability.
First Major Advance in Treatment of Lung Cancer in Years
March 1st 1999A cooperative national clinical trial has produced the first major treatment advance in years for small-cell lung cancer. The study, which was published in the February 1999 issue of the New England Journal of Medicine, used two treatments of radiation daily, combined with chemotherapy, compared to the usual practice of delivering one radiation dose per day. Specifically, the protocol covered small-cell lung cancer limited to one-half of the chest area.
LAMP to Evaluate RT Plus Chemotherapy for Lung Cancer
February 1st 1999RESTON, Virginia-A new national clinical study known as LAMP (locally advanced multimodality protocol) will help evaluate the best manner in which to give patients radiation and chemotherapy to treat locally advanced, non-small-cell lung cancer (NSCLC). The trial, conducted by the American College of Radiology (ACR), is using the chemotherapy agents paclitaxel (Taxol) and carboplatin (Paraplatin).
Irinotecan Active in Advanced NSCLC, Esophageal Cancer
February 1st 1999NEW YORK-Preliminary data presented at the Chemotherapy Foundation Symposium XVI suggest that the toposiomerase I inhibitor irinotecan (Camptosar) in combination with other chemotherapy agents may be effective in multiple tumor types, including advanced non-small-cell lung cancer (NSCLC) and advanced esophageal cancer.
Trial Uses Vitamin A To Prevent Lung Cancer in Former Smokers
January 1st 1999HOUSTON-There are currently 581 clinical trials underway at The University of Texas M.D. Anderson Cancer Center, John Mendelsohn, MD, the Center’s president, said at a seminar held in conjunction with the opening of the Center’s new Alkek Hospital .
Hycamtin Is Approved for Use in Relapsed SCLC
January 1st 1999PHILADELPHIA-SmithKline Beecham’s topoisomerase I inhibitor Hycamtin (topotecan HCl for injection) has received FDA approval for the treatment of small-cell lung cancer (SCLC) after failure of first-line chemotherapy. The agent was previously approved for use in ovarian cancer after failure of initial or subsequent chemotherapy.
Taxol May Improve Survival in Advanced NSCLC
January 1st 1999ATHENS-Patients with inoperable non-small-cell lung cancer (NSCLC) who receive paclitaxel (Taxol) together with best supportive care survive significantly longer than those managed with best supportive care alone, according to results from a phase III, randomized trial conducted at six sites in the United Kingdom and Canada, and presented at the European Society for Medical Oncology (ESMO) congress.
NCI to Sponsor Phase III Trials of Liquid Shark Cartilage Angiogenesis Inhibitor
January 1st 1999The National Cancer Institute (NCI) will sponsor phase III trials to test the efficacy of AE-941/Neovastat, an angiogenesis inhibitor developed by AEterna Laboratories Inc., a Canadian biotechnology corporation, in the treatment of cancer.
Patients Learn About New Therapeutic Options for Lung Cancer
January 1st 1999NEW YORK-The availability of new therapeutic options are focusing more attention on lung cancer, a disease for which advances have been slow in coming, said Ronald Blum, MD, director of the Comprehensive Cancer Center and chief of oncology, St. Vincent’s Hospital and Medical Center, New York City. He discussed these advances during a Cancer Care, Inc., teleconference for patients.
Open Lung Biopsy Cost-Effective in Evaluating Solitary Pulmonary Nodules
January 1st 1999Surgical excision not only is the most accurate method of evaluating a solitary pulmonary nodule, it is also the most cost effective, said Stephen C. Yang, md, Johns Hopkins assistant professor of surgery at the 1998 meeting of The American
Vinorelbine/Cisplatin Improves Survival In Advanced NSCLC
November 1st 1998DETROIT--A regimen combining vinorelbine (Navelbine) with cisplatin (Platinol) improved survival in patients with advanced non-small-cell lung cancer (NSCLC) over that achieved with cisplatin alone, said Antoinette Wozniak, MD, associate professor of clinical oncology, Wayne State University Medical School, Karmanos Cancer Institute.
Gemzar Gets Indication for First-Line Treatment of NSCLC
November 1st 1998INDIANAPOLIS--Eli Lilly and Company’s Gemzar (gemcitabine) has received FDA approval for use as first-line treatment of inoperable, locally advanced, or metastatic non-small-cell lung cancer (NSCLC) in combination with cisplatin (Platinol). The agent was previously approved as first-line, single-agent therapy of locally advanced or metastatic pancreatic cancer
Panel Recommends Photofrin for Use in Late-Stage Lung Cancer
October 1st 1998BETHESDA, Md--A Food and Drug Administration panel has urged expanding the use of Photofrin (porfimer sodium, QLT PhotoTherapeutics) in lung cancer. In a unanimous vote, the Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA approve the photodynamic therapy (PDT) for reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial non-small-cell lung cancer (NSCLC).
Research May Provide Insights Into Best Treatment of Elderly Cancer Patients
September 1st 1998New studies examining chemotherapy regimens for elderly patients with breast and lung cancer and data showing significant underrepresentation of the elderly in major clinical trials were discussed at a press conference at the 34th Annual Meeting of
ODAC Recommends Approval of Topotecan for Second- Line Treatment of Small-Cell Lung Cancer
August 1st 1998The FDA’s Oncologic Drugs Advisory Committee (ODAC) recommended the approval of topotecan hydrochloride for injection (Hycamtin) for the second-line treatment of sensitive small-cell lung cancer (SCLC).
Irinotecan Plus Cisplatin in Patients With Advanced Non- Small-Cell Lung Cancer
During the 1980s, platinum-based regimens were yielding response rates typically less than 25%, median survival durations of about 25 weeks, and 1-year survival rates less than 25% in patients with advanced non-small-cell lung
Survival Benefit Seen With Multimodality Therapy in NSCLC
July 1st 1998CHICAGO--A role is emerging for multimodality therapy in the treatment of both resectable and unresectable stage III non-small-cell lung cancer (NSCLC). When given as an adjunct to radiotherapy or surgery, chemotherapy can downstage local disease and control systemic disease spread by eliminating micro-metastases or delaying the development of metastases, Ann Mauer, MD, a senior fellow in oncology at the University of Chicago, said at the International Conference of the American Thoracic Society and American Lung Association.
Quality of Life in NSCLC May Be Difficult to Measure
July 1st 1998CHICAGO--Monitoring instruments that evaluate the symptoms and psychosocial problems of patients with non-small-cell lung cancer (NSCLC) may not provide clear answers regarding the quality of patients’ lives because they are difficult to analyze and they measure aspects of quality that are not affected by chemotherapy, said Richard Gralla, MD, chief of immunology and oncology and director of the Ochsner Cancer Center, New Orleans.
Gemcitabine/Cisplatin Superior to Cisplatin Alone in Advanced NSCLC
July 1st 1998INDIANAPOLIS--Patients with advanced non-small cell lung cancer (NSCLC) have higher response rates, longer time to progression, and better overall survival with gemcitabine (Gemzar) plus cisplatin (Platinol) than with cis-platin alone, according to data from a multicenter, randomized, phase III study presented at the annual ASCO meeting.
ELVIS Favors Vinorelbine for Elderly With NSCLC
July 1st 1998NAPLES, Italy--Platinum-based chemotherapy is often avoided in elderly lung cancer patients due to concerns about tolerability. Since about one-third of patients with non-small cell lung cancer (NSCLC) are over age 70 at diagnosis, this presents a significant problem.
Combination More Effective Than High-Dose Cisplatin in NSCLC
July 1st 1998HAMBURG, Germany--Increasing cisplatin dose intensity was less effective than combining standard cisplatin (Platinol) with paclitaxel (Taxol) in a multicenter multinational study of advanced non-small cell lung cancer (NSCLC) reported at ASCO.
PDT Improves QOL in Lung Cancer Patients Who Have Endobronchial Obstruction
July 1st 1998LOUISVILLE, Kentucky--Photodynamic therapy (PDT) offers a simple and effective alternative to conventional techniques for palliative debridement of endobronchial obstructions in lung cancer patients, data from two clinical trials suggest.
Twice-Daily Intensive RT Improves SCLC Survival Rates
July 1st 1998LOS ANGELES--Twice-daily chest irradiation concurrent with cycle 1 chemotherapy substantially improves survival and reduces the rate of local failure in limited stage small-cell lung cancer (SCLC), compared with a less intensive once-daily schedule, a large intergroup trial has shown.
Adenoviral-p53 Gene Therapy Promising in NSCLC
July 1st 1998HOUSTON--Adenoviral-p53 gene therapy with Introgen Therapeutics’ INGN 201 was well tolerated and showed evidence of clinical activity both alone and with cisplatin (Platinol) in patients with advanced non-small-cell lung cancer (NSCLC) who had failed conventional therapy. Stephen Swisher, MD, of the M. D. Anderson Cancer Center, presented the completed phase I/II trial results at an ASCO poster session.
ODAC Recommends Non-Small-Cell Lung Cancer Indication for Gemcitabine
July 1st 1998The FDA’s Oncologic Drugs Advisory Committee (ODAC) recommended that gemcitabine HCl (Gemzar) be approved both as a single agent and in combination with cisplatin (Platinol) for the treatment of locally advanced or metastatic non-small-cell
Three-Drug Combination May Improve Response Rates in NSCLC Patients
July 1st 1998NASHVILLE--Adding gemcitabine (Gemzar) to the widely used combination of paclitaxel (Taxol) and carboplatin (Paraplatin) may increase the response rate in advanced non-small-cell lung cancer (NSCLC), compared with the two-drug combination, a phase I/II study has shown.